Vor Bio announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective September 30, 2024. Dr. Choi brings over twenty-five years of experience in public and private investment management, business development, and corporate strategy within the pharmaceutical and biotechnology industry.
His expertise in structuring corporate partnerships, managing complex transactions, and capital markets strategy is expected to play a critical role as Vor Bio advances its clinical pipeline. Prior to joining Vor Bio, Dr. Choi was a Principal at Oracle Investment Management, Inc., a hedge fund specializing in healthcare investments.
In connection with his appointment, Dr. Choi was granted stock options to purchase an aggregate of 400,000 shares of Vor Bio’s common stock. These options were granted as a material inducement to employment and will vest over a four-year period.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.